Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.
In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following list of names for the drugs described are "under consideration" by the USAN Council:
|gallium ga 68 dotate||tumor imaging agent|
|lutetium lu 177 dotate||treatment of cancer|
|ajulemic acid||treatment of cystic fibrosis|
|bocomarsen||treatment of hematologic malignancies|
|empluzumab||treatment of cancer|
|flaxalizumab||treatment of hematologic cancers|
|momorsen||treatment of hematologic malignancies|
|relaplumab||treatment of cancer|
|rivogenleucel-l||graft vs. host disease; genetically modified allogeneic cellular therapy|
|setigentucel-l||treatment of pancreatic cancer|
|spirociclib||reduction of chemotherapy-induced myelosuppression|
|trilaciclib||reduction of chemotherapy-induced myelosuppression|
|vispetinib||treatment of cancer|
|eberlixizumab||treatment of allergic asthma|
|finradenoson||treatment of cancer|
|namidenoson||treatment of cancer|
|netodenoson||treatment of cancer|
|temivirsen||treatment of hepatitis C|